Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $25.00 | Equal-Weight | Stephens |
| 9/6/2024 | $35.00 | Outperform | RBC Capital Mkts |
| 8/7/2024 | $33.00 → $28.00 | Buy → Neutral | B. Riley Securities |
| 9/11/2023 | Neutral → Buy | B. Riley Securities | |
| 8/31/2022 | Outperform | Cowen | |
| 7/28/2022 | $30.00 | Overweight | Barclays |
| 7/6/2022 | $60.00 | Buy | Canaccord Genuity |
| 4/13/2022 | $62.00 → $33.00 | Buy → Neutral | B. Riley Securities |
EFFECT - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
SCHEDULE 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
SCHEDULE 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
Continued advancement across research and development pipeline, with key program updates expected in 2H 2025 Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer open and actively recruiting patients Strengthened clinical leadership and bolstered roster of scientific advisors with additions to Board of Directors and creation of Research and Innovation Advisory Board Strategic cost realignment of approximately 30%, primarily through a workforce reduction Cash and cash equivalents of $721.5 million as of June 30, 2025, with expected financial runway extended into 2028 Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pio
HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b
Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on July 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 77,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price equal to $6.95 per share, Bicycle Therapeutics' closing trading price on June 30, 2025, and will vest over four years, with 25%
Stephens initiated coverage of Bicycle Therapeutics with a rating of Equal-Weight and set a new price target of $25.00
RBC Capital Mkts initiated coverage of Bicycle Therapeutics with a rating of Outperform and set a new price target of $35.00
B. Riley Securities downgraded Bicycle Therapeutics from Buy to Neutral and set a new price target of $28.00 from $33.00 previously
HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b
Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer; Duravelo-2 dose selection data expected in 2H 2025 Enhanced response to zelenectide pevedotin seen in NECTIN4 gene-amplified late-line breast cancer and non-small cell lung cancer (NSCLC), resulting in U.S. FDA Fast Track designations for triple-negative breast cancer and NSCLC; several Phase 1/2 trials expected to start in 2025 Advancing radiopharmaceuticals pipeline, with additional MT1-MMP human imaging data expected in mid-2025 and first EphA2 human imaging data planned for
Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the company's clinical oncology programs. "We are delighted to welcome Skip, Markus and Niklas to our Clinical Advisory Board. Each of them has dedicated their careers to advancing the care of patients with cancer through the development of novel therapeutics," said Bicycle Therapeutics CEO Kevin Lee, Ph.D. "Their expertise will provide invaluable guidance
Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025 Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated an enhanced response to zelenectide pevedotin Company to advance development strategy leveraging NECTIN4 gene amplification, with Phase 1/2 trials in breast cancer, lung cancer and multi-tumor planned for 2025 Bicycle Therapeutics to host conference call and webcast with management and
Abstract outlines data showing enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer patients with NECTIN4 gene amplification Company to announce topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer Conference call and webcast scheduled for Friday, Dec. 13, at 7 a.m. CT to review all data Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the
First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use Additional preclinical data demonstrate biodistribution of BRCs can be optimized to maintain high tumor uptake while significantly reducing kidney levels Company strategy focuses on pursuing novel targets using a range of isotopes to develop radiopharmaceuticals with first-in-class potential Bicycle Therapeutics to host conference call and webcast today at 8 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therap
SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
3 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)